Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4120 participants.

Also called NCT07746271

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 4,120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07746271
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07746271. Randomized; no masking; primary purpose prevention. Start 2026-09-30 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial
Acronym
GOALPOST
Condition
Hypertension in Pregnancy
Condition
Obstetrical Complications
Intervention (Drug)
Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg
Intervention (Other)
Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg
Lead sponsor
The George Washington University Biostatistics Center (class: other)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (class: US National Institutes of Health)
Collaborator
University of Alabama at Birmingham (class: other)
Collaborator
University of Utah (class: other)
Collaborator
Brown University (class: other)

Record details

Record id
cardio:ct-nct07746271
Content hash
423479bb4512d049e16163003d055b9e532501c44c76eb440065a5b92ecd39f1